FinscoFinsco

Edwards Lifesciences (US.EW)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.EW · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion-→
ROE-→
Cash Conversion0.0%↓
D/E Ratio-→
Gross Margin77.7%→
US.EW (Edwards Lifesciences) | YoY: 2026 H1 vs 2025 H1


Metric           Value  YoY
---------------------------
FCF Conversion       -    →
ROE                  -    →
Cash Conversion   0.0%    ↓
D/E Ratio            -    →
Gross Margin     77.7%    →
Key Metrics
US.EW (Edwards Lifesciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
---------------------------
FCF Conversion - →
ROE - →
Cash Conversion 0.0% ↓
D/E Ratio - →
Gross Margin 77.7% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies